1 One case of infusion reaction and one case of pruritus, both Grade 1 and resolved without medication. 2 One case of asymptomatic increased lipase, isolated to Day 43 post-dose (Grade 3); One case of ...
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell ...
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results